Artigos de revistas sobre o tema "320.9/8/003"
Siga este link para ver outros tipos de publicações sobre o tema: 320.9/8/003.
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "320.9/8/003".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
1
Baillif, Stéphanie, Pascal Staccini, Michel Weber, Marie-Noëlle Delyfer, Yannick Le Mer, Vincent Gualino, Laurence Collot et al. "Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant". Pharmaceutics 14, n.º 11 (5 de novembro de 2022): 2391. http://dx.doi.org/10.3390/pharmaceutics14112391.
Texto completo da fonteResumo:
To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (73.5%) were switched 1–8 weeks after their last DEXi. The mean best-corrected visual acuity improved to 59.8 letters at month 4 and remained stable during the follow-up. The mean central macular thickness (CMT) significantly decreased during the follow-up, with a minimum of 320.9 μm at month 3. The baseline CMT was higher in eyes that received the last DEXi >8 weeks versus <8 weeks before the first FAci (p < 0.021). After FAci injection, additional treatments were needed in 37 (32.7%) eyes. A longer diabetes duration (p = 0.009), a longer time between the last DEXi and the first FAci (p = 0.035), and a high baseline CMT (p = 0.003) were risk factors for additional treatments. The mean intraocular pressure was <19 mmHg at all timepoints, with no difference between eyes receiving the last DEXi ≤8 weeks or >8 weeks before the switch. Switching from DEXi to FAci in DME is effective and safe. A short time between the last DEXi and the first FAci reduced CMT fluctuations and the need for early additional treatments.
2
Kouraklis, Gregory. "To the Editor (DOI: 10.1007/s00268-003-7318-8)". World Journal of Surgery 28, n.º 4 (1 de abril de 2004): 431–33. http://dx.doi.org/10.1007/s00268-003-7318-8.
Texto completo da fonte
3
Putri, Andini Octaviana, Dominicha Ernalem Tarigan, Emelia Agustina, Laura Oksin Kawalo e Muhammad Saidi Hidayat. "POS PEMKES HIPERTENSI (POS PEMERIKSAAN KESEHATAN HIPERTENSI) DAN EDUKASI HIPERTENSI DI WILAYAH RT.003 RW.003 KELURAHAN GUNTUNG PAIKAT, KECAMATAN BANJARBARU SELATAN, KOTA BANJARBARU, KALIMANTAN SELATAN". SELAPARANG: Jurnal Pengabdian Masyarakat Berkemajuan 6, n.º 2 (8 de junho de 2022): 877. http://dx.doi.org/10.31764/jpmb.v6i2.8705.
Texto completo da fonteResumo:
ABSTRAKHipertensi adalah suatu kondisi dimana seseorang mengalami peningkatan tekanan darah di atas ambang batas normal. Ambang batas tekanan darah normal untuk orang dewasa adalah 90/60 mmHg dan 120/80 mmHg. Tujuan penelitian ini adalah menganalisis kejadian hipertensi di RT.003 RW.003 Guntung Paikat, Banjarbaru Selatan, dan Kalimantan Selatan berdasarkan riwayat hipertensi pada penduduk setempat. Metode survei yang digunakan adalah metode kuantitatif dengan desain survei cross sectional. Kuesioner berupa pre-test dan post-test serta format sample tes tekanan darah yang difungsikan sebagai alat uji. Responden penelitian ini adalah penduduk di RT.003 RW.003 Guntung Paikat, Banjarbaru Selatan, dan Kalimantan Selatan yang memiliki riwayat hipertensi. Metode pengambilan sampel dilakukan dengan menggunakan kuesioner faktor risiko yang dilanjutkan dengan diagnosa komunitas. Dari hasil sampling didapatkan 13 dari 155 sampel (8,4%) memenuhi kriteria (memiliki riwayat hipertensi), namun hanya 8 orang yang mengikuti program intervensi posyandu dan penyuluhan hipertensi. Hasil pre-test yang diperoleh benar oleh 6 dari 8 responden (75%), sedangkan hasil post-test yang diperoleh sebanyak 7 responden (87,5%). Dari 8 responden yang menjawab benar. Hasil pemeriksaan tekanan darah pada lebih dari 8 dari 8 sampel (100%) adalah hipertensi. Dari sini dapat disimpulkan bahwa angka hipertensi RT.003 RW.003 Guntung Paikat, Banjarbaru Selatan dan Kalimantan Selatan sangat tinggi dan memerlukan intervensi lebih lanjut. Kata kunci: hipertensi; penyuluhan kesehatan; intervensi. ABSTRACTHypertension is a condition in which a person experiences an increase in blood pressure that exceeds the normal threshold. The blood presure normal threshold for adult is 90/60 mmHg- 120/80 mmHg. The purpose of this research is to analyze the incidence of hypertension in RT.003 RW.003 Guntung Paikat, Banjarbaru Selatan, Kalimantan Selatan based on the hypertension history of local residents. The research method used is a quantitative method with a cross-sectional research design. The research instrument used is a questionnaire in the form of pre-test and post-test and sample’s blood pressure check result sheet. The respondent of this research are the local resident which have a hypertension history. Sampling technique is done by using the risk factor questionnaire, which is followed by community diagnosis. As for the result obtained from sampling, namely from 155 samples there are 13 samples (8,4%) that conform the criteria (has a hypertension history), but who was present the health checkpoint intervention program and hypertension education only 8 people/sampels. The result of the pre-test obtained show that as many as 6 respondents (75%) out of 8 respondents who answered correctly, whereas the result of the post-test obtained show that as many as 7 respondents (87,5%) out of 8 respondents who answered correctly. The result of the blood pressure checks as many as 8 sampels (100%) out of 8 sampels are hypertension. So that the conclusion is the hypertension rate in RT.003 RW.003 Guntung Paikat, Banjarbaru Selatan, Kalimantan Selatan is quite high and need a follow-up intervention. Keywords: hypertension; health education; intervention.
4
Eid, S., N. Alsafar, S. Alqatan e H. Metwalle. "P.8.a.003 Polypharmacy among psychiatric outpatients in Kuwait". European Neuropsychopharmacology 20 (agosto de 2010): S631. http://dx.doi.org/10.1016/s0924-977x(10)70968-8.
Texto completo da fonte
5
Jagodic, H. Korosec, B. Korosec, D. Lajlar, V. Winkler Skaza, V. Novak, K. Jagodic e L. Pintaric. "P.8.a.003 Involuntary treatment is better than no treatment". European Neuropsychopharmacology 18 (agosto de 2008): S568. http://dx.doi.org/10.1016/s0924-977x(08)70867-8.
Texto completo da fonte
6
Koukouna, D., L. Bossini, F. Pellegrini, I. Casolaro, C. Caterini e A. Fagiolini. "P.8.b.003 Light therapy as a treatment for sexual dysfunction". European Neuropsychopharmacology 25 (setembro de 2015): S655. http://dx.doi.org/10.1016/s0924-977x(15)30931-7.
Texto completo da fonte
7
Lorenzi, P., e E. Angeli. "P.8.a.003 Huber basic symptoms (HBS) and eating disorders (ED)". European Neuropsychopharmacology 16 (janeiro de 2006): S536. http://dx.doi.org/10.1016/s0924-977x(06)70745-3.
Texto completo da fonte
8
Liu, Yahong, Longfei Miao, Yuying Guo e Hongqi Tian. "Preclinical Evaluation of Safety, Pharmacokinetics, Efficacy, and Mechanism of Radioprotective Agent HL-003". Oxidative Medicine and Cellular Longevity 2021 (20 de fevereiro de 2021): 1–11. http://dx.doi.org/10.1155/2021/6683836.
Texto completo da fonteResumo:
Amifostine is a radioprotector with high efficacy but poor safety, short half-life, no oral formulation, and poor compliance, which limits its application. With the increasing risk of exposure to radiation, the development of new radioprotective agents is critical. We previously synthesized a new amifostine derivative, the small molecule compound HL-003. In this study, we focused on evaluating the radioprotective properties of HL-003. Using the in vitro 2,2-diphenyl-1-picrylhydrazyl assay, we initially confirmed HL-003 as a strong antioxidant and demonstrated that its free radical scavenging activity was stronger than that of amifostine. Then, we performed an acute toxicity test, a 28-day toxicity test, a 30-day survival rate test, and a pharmacokinetic study, all of which provided aggregate evidence that HL-003 functioned as a small molecule radioprotector with high efficacy, a favorable safety profile, a long half-life, and oral administration. The intestinal radioprotective mechanism of HL-003 was explored in male C57 mice after abdominal irradiation by analyzing intestinal tissue samples with hematoxylin-eosin staining, immunohistochemistry, TUNEL staining, and immunofluorescence detection. The results showed that HL-003 protected intestinal DNA from radiation damage and suppressed the expression of phosphorylated histone H2AX, phosphorylated p53, and the apoptosis-related proteins caspase-8 and caspase-9, which contributed to maintaining the normal morphology of the small intestine and provided insights into the mechanism of radioprotection. Thus, HL-003 is a small molecule radioprotector with a potential application in radiation medicine.
9
Nurnainah, Nurnainah, e Sitti Badria Asikin. "Penyuluhan tentang Inisiasi Menyusui Dini untuk Mencegah Penyakit Stunting pada Anak". Jurnal Peduli Masyarakat 1, n.º 1 (28 de dezembro de 2019): 31–34. http://dx.doi.org/10.37287/jpm.v1i1.156.
Texto completo da fonteResumo:
Penyuluhan yang di lakasanakan dengan tujuan untuk menekan jumlah penderita Stunting di Indonesia. Penyuluhan ini di laksanakan pada tanggal 08 Agustus 2019 di ORT 003 kelurahan maricaya kecamatan Makassar penyuluhan ini di laksanakan dengan jumlah peserta yang hadir sebanyak 30 orang yang terdiri dari ibu hamil dan ibu menyusui yang berdomisili di ORT 003 keluraham Maricaya kecamatan Makassar. Kegiatan ini teridiri dari 2 sesi dan berjalan dengan lancar.
Kata kunci: anak; inisiasi; menyusui; stunting
COUNSELING ABOUT EARLY BREASTFEEDING INITIATIVES TO PREVENT STUNTING IN CHILDREN
ABSTRACT
Counseling is held with the aim of reducing the number of people suffering from stunting in Indonesia. This counseling was held on August 8, 2019 at ORT 003, Maricaya sub-district, Makassar sub-district, this counseling was carried out with 30 participants consisting of pregnant women and nursing mothers who live in ORT 003, Maricaya sub-district, Makassar sub-district. This activity consisted of 2 sessions and went well.
Keywords: breastfeeding; children; initiation; stunting
10
Fristika, Yessy Octa. "GAMBARAN PENGETAHUAN DAN SIKAP IBU TENTANG GERAKAN 1000 HARI PERTAMA KEHIDUPAN". JURNAL KESEHATAN INDRA HUSADA 9, n.º 2 (27 de dezembro de 2021): 33–42. http://dx.doi.org/10.36973/jkih.v9i2.321.
Texto completo da fonteResumo:
1000 Hari Pertama Kehidupan adalah periode percepatan tumbuh kembang yang dimulai sejak terbentuknya janin dalam kandungan hingga anak berusia 2 tahun. Pada periode tersebut, terjadi perkembangan otak, pertumbuhan badan, perkembangan sistem metabolisme tubuh dan pembentukan sistem kekebalan tubuh yang begitu cepat. Penelitian ini bertujuan untuk melihat Gambaran Pengetahuan dan Sikap Ibu tentang Gerakan 1000 Hari Pertama Kehidupan di RT.003 RW.003 Tanjung Bubuk, Kel. Bukit Baru, Kec. Ilir Barat I Palembang Tahun 2020. Penelitian ini menggunakan desain deskriptif dengan pendekatan cross sectional. Analisa yang digunakan adalah univariat. Sampel penelitian yang diambil secara purposive sampling. jumlah sampel dalam penelitian ini adalah berjumlah 20 orang sampel. Berdasarkan penelitian pengetahuan bahwa sebagian besar ibu memiliki pengetahuan yang tidak baik yaitu 16 orang (80%) dan ibu yang memiliki pengetahuan yang baik yaitu 4 orang (20%). Berdasarkan sikap bahwa sikap ibu terhadap gerakan 1000 hari pertama kehidupan memiliki sikap tidak baik sebanyak 12 orang (60%) dan sikap ibu yang baik sebanyak 8 orang (40%). Hasil penelitian ini merekomendasikan kepada Ketua RT.003 RW.003 dan masyarakat di RT.003 RW.003 untuk meningkatkan informasi tentang kesehatan khususnya tentang gerakan 1000 Hari Pertama Kehidupan. Rekomendasi ini juga diberikan untuk para peneliti lain yang bermaksud mengadakan penelitian tentang gerakan 1000 HPK agar melibatkan lebih banyak sampel dan variabel yang diteliti dengan desain yang berbeda serta menggunakan instrument yang telah memiliki nilai validitas dan reliabilitas baku.
11
Abbasi, S., e A. Honaramooz. "305 OPTIMIZING DONOR AND RECIPIENT FACTORS IN XENOGRAFTING OF TESTIS TISSUE". Reproduction, Fertility and Development 22, n.º 1 (2010): 308. http://dx.doi.org/10.1071/rdv22n1ab305.
Texto completo da fonteResumo:
Grafting of donor mammalian testis tissue into recipient mice allows completion of spermatogenesis in the grafted tissue and therefore can serve as a new option for preservation of male germ line. For testis tissue xenografting, castrated male nude mice typically serve as recipients, each receiving 8 testis tissue fragments; however, no study has comprehensively investigated donor and recipient factors. The objective of this study was to determine the effects of strain of immunodeficient recipient mouse (nude v. SCID), gonadal status (intact v. gonadectomized), and gender (male v. female) on the outcome of testis tissue xenografting. A secondary objective was to determine the optimal number of testis tissue fragments per mouse most suitable for xenografting. Testis parenchyma from newborn piglets were cut into small fragments (5 mg each) and grafted under the back skin of different groups of immunodeficient mice. In Experiment 1, 8 groups of mice (n = 7/group) served as recipients: castrated male nude, intact male nude, ovariectomized female nude, intact female nude, castrated male SCID, intact male SCID, ovariectomized female SCID, and intact female SCID. In Experiment 2, 4 groups of mice (n = 10/group) served as recipients of 2, 4, 8, or 16 testis tissue fragments per mouse. Recipient mice were sacrificed 8 months after grafting and the weight of the grafts and vesicular glands (male mice) were compared among groups by analysis of variance. In Experiment 1, mouse gonadal status (intact v. gonadectomized) did not affect the total graft weight (P > 0.05), but both the recipient mouse strain (nude v. SCID) and gender (male v. female) affected the total graft weight (2460 ± 320.9, 1420 ± 290.0, 758 ± 156.7, and 2780 ± 297.4, mean ± SEM, P < 0.0001 for SCID, nude, female, and male mice, respectively). In Experiment 2, the total graft weight was highest in the group of mice receiving 8 testis tissue fragments (192 ± 76.1, 695 ± 96.5, 2443 ± 338.8, and 1458 ± 305.4, mean ± SEM, P < 0.0001 for 2, 4, 8, or 16 fragment groups, respectively). These results collectively indicate that male SCID mice receiving 8 testis tissue fragments provide optimized conditions for the recovery of largest grafts. Research was supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Saskatchewan Health Research Foundation (SHRF) to A. Honaramooz and scholarships from the Western College of Veterinary Medicine and the International Peace Scholarship to S. Abbasi.
12
Wu, Hongmei. "'Multilingualism across the lifespan' Unn Røyneland and Robert Blackwood (eds) (2022)". Sociolinguistic Studies 17, n.º 4 (17 de novembro de 2023): 469–74. http://dx.doi.org/10.1558/sols.25828.
Texto completo da fonteResumo:
Multilingualism across the lifespanUnn Røyneland and Robert Blackwood (eds) (2022)London and New York: Routledge. Pp. 252ISBN: 978-0-367-64682-0 (hbk)ISBN: 978-0-367-64686-8 (pbk)ISBN: 978-1-003-12581-5 (ebk)
13
Reincke, Martin, Michael Peter, Wolfgang G. Sippell e Bruno Allolio. "Impairment of 11β-hydroxylase but not 21-hydroxylase in adrenal 'incidentalomas'". European Journal of Endocrinology 136, n.º 2 (fevereiro de 1997): 196–200. http://dx.doi.org/10.1530/eje.0.1360196.
Texto completo da fonteResumo:
Abstract Recent reports have shown an exaggerated response of 17-hydroxyprogesterone in up to 70% of patients with incidentally detected adrenal adenomas ('incidentalomas'). This has been explained by pre-existing 21-hydroxylase deficiency which may be a pathogenetic factor in the development of adrenal tumours. However, other defects in steroidogenesis, such as mild 11β-hydroxylase deficiency, could also result in increased 17-hydroxyprogesterone secretion. We therefore studied the glucocorticoid and mineralocorticoid pathways in patients with adrenal 'incidentalomas' by measuring multiple adrenal steroids before and after 1–24 ACTH stimulation. Twenty patients with adrenal 'incidentalomas' (14 females, 6 males) and 27 healthy controls (14 females, 13 males) were studied. All subjects underwent a 1–24 ACTH stimulation test (250 μg i.v.) with determination of progesterone, 11-deoxycorticosterone, corticosterone, 17-hydroxyprogesterone, 11-deoxycortisol and cortisol at O and 60 min. All steroids were measured by RIA after extraction and HPLC. Patients with 'incidentalomas' had higher stimulated concentrations of 17-hydroxyprogesterone (21·6 ± 8·4 vs 4·2 ± 0·3 nmol/l; P ≤ 0·001), 11-deoxycortisol (8·1 ± 1·2 vs 3·6 ± 0·3 nmol/l; P ≤ 0·001), progesterone (8·28 ± 2·82 vs 1·08 ± 0·15 nmol/l; P ≤ 0·001), and 11-deoxycorticosterone (2·1 ± 0·39 vs 0·78 ± 0·12 nmol/l; P = 0·002) compared with controls. In contrast, cortisol and corticosterone concentrations were not different. There was evidence for impairment of 11β-hydroxylase activity by an increased 11-deoxycortisol/cortisol ratio (0·012 ± 0·003 vs 0·005 ± 0·001 in controls; P = 0·002) and 11-deoxycorticosterone/corticosterone ratio (0·04 ± 0·003 vs 0·015 ± 0·003; P = 0·003). The conclusions reached were that patients with adrenal 'incidentalomas' have increased responses of precursors of the mineralocorticoid and glucocorticoid pathway including 17-hydroxyprogesterone after stimulation with ACTH. This seems to be caused by impairment of 11β-hydroxylase activity rather than by impaired 21-hydroxylase activity in these tumours. European Journal of Endocrinology 136 196–200
14
Gairola, Vineet. "The Future of Religious Studies in India, edited by Clemens Cavallin, Åke Sander, and Sudha Sitharaman". Religions of South Asia 18, n.º 1-2 (11 de junho de 2024): 239–41. http://dx.doi.org/10.1558/rosa.28985.
Texto completo da fonteResumo:
The Future of Religious Studies in India, edited by Clemens Cavallin, Åke Sander, and Sudha Sitharaman. Delhi: Routledge India, 2021. v + 214 pp., £104 (hb), £31.19 (ebook). ISBN 978-1-138-50176-8 (hb), 978-1-003-12011-7 (ebook).
15
Mohanty, Sasmita. "Book review: K. A. Busia, The Challenge of Africa". Insight on Africa 16, n.º 2 (23 de maio de 2024): 253–55. http://dx.doi.org/10.1177/09750878231213910.
Texto completo da fonteResumo:
K. A. Busia, The Challenge of Africa (New York: Routledge Taylor and Francis Group in Cooperation with BFI Publication, 2023), 151 pp., ₹7,140.00. ISBN 978-1-032-24793-9 (Hardback), ISBN 978-1-032-24851-6 (Paperback), ISBN 978-1-003-28040-8 (e-book).
16
Dixon, Katherine Chyna. "Book review: Pettenati, G. 2022: Landscape as Heritage: International Critical Perspectives". Progress in Development Studies 24, n.º 1 (janeiro de 2024): 80–82. http://dx.doi.org/10.1177/14649934231205609.
Texto completo da fonteResumo:
Pettenati, G. 2022: Landscape as Heritage: International Critical Perspectives. London and New York: Taylor and Francis. 328 pp. £130.00 (cloth), £32.39 (e-book), £35.99 (paper). ISBN: 978-1-032-04934-2 (cloth), 978-1-003-19523-8 (e-book), 978-1-032-04623-5 (paper).
17
Amin, Asim, Arkadiusz Dudek, Theodore Logan, Raymond S. Lance, Jeffrey M. Holzbeierlein, Viraj A. Master, Sumanta Kumar Pal et al. "Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)." Journal of Clinical Oncology 31, n.º 6_suppl (20 de fevereiro de 2013): 357. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.357.
Texto completo da fonteResumo:
357 Background: During the past decade, VEGF targeted therapies have become standard treatment for advanced RCC. While targeted therapies have yielded improved efficacy, durable remissions are rare, particularly in unfavorable risk subjects. In a pivotal trial, treatment with sunitinib yielded a median OS of 5.3 months for poor risk and 20.7 months for intermediate risk subjects. Similarly, the validation dataset for the Heng risk model (ASCO 2011) revealed a median OS of 8 months for poor risk and 21 months for intermediate risk patients treated with VEGF targeted therapies. Durable responses have been elicited by immunotherapy in RCC. We report an update on patients with mRCC treated with combined VEGF TKI (sunitinib) plus autologous immunotherapy (AGS-003). Methods: In this phase II study, subjects with unfavorable prognosis mRCC (poor and intermediate risk) were treated with sunitinib plus autologous dendritic cell immunotherapy (AGS-003). Treatment consisted of standard 6-week cycles of sunitinib plus AGS-003 (once every 3 weeks x5 doses, then every 12 weeks until PD). Tumor response was assessed per RECIST and subjects were followed for PFS and OS. Immune monitoring samples were taken at screening, baseline and after the third and fifth doses of AGS-003 and analyzed by multiparametric flow cytometry. Results: 21 subjects were treated. As previously reported, the median overall PFS was 11.2 months and the final median OS was 30.2 months. When analyzed by baseline Heng risk status, the median PFS was 19.4 months for intermediate (n=11) and 5.8 months for subjects with poor risk features (n=10) at baseline. The median OS is 39.5+ months for intermediate and 9.1 months for subjects with poor risk. Conclusions: The results from this single-arm phase II study represent a near doubling of expected PFS and OS for unfavorable risk subjects treated with AGS-003 plus sunitinib. Updated survival and immunologic findings will be presented, as 8 of 21 subjects are still alive and continue to be followed. These results support the ongoing phase III ADAPT study, which is designed to validate these encouraging clinical and immunologic findings. Clinical trial information: NCT00678119.
18
CASTRO, Arizaldo E., e Cristina C. SALIBAY. "Anti-Methicillin Resistant Staphylococcus aureus (MRSA) Activity of Pseudoalteromonas flavipulchra Isolated from Marine Waters of Batangas, Philippines". Walailak Journal of Science and Technology (WJST) 17, n.º 6 (1 de junho de 2020): 570–78. http://dx.doi.org/10.48048/wjst.2020.4789.
Texto completo da fonteResumo:
The ocean boasts untapped novel producers of antibiotic substances in the form of unicellular organisms. One of the newest bioproducers of pharmacologically-significant substances studied for its potential against clinically-significant pathogens is the genus Pseudoalteromonas, a gammaproteobacterial group. This study is a preliminary report detailing the isolation of a Pseudoalteromonas flavipulchra species from Philippine marine waters. The isolate coded as PAM-003 was identified as 100 % similar to P. flavipulchra strain NCIMB2033 through 16s rRNA gene amplification and sequencing. PAM-003 was allowed to produce bioactives for 12 days. Afterwards, non-polar products were isolated from the base medium through membrane filtration, organic solvent extraction and rotary evaporation. The crude solution of bioactives injected in sterile discs was used for disc-diffusion assay against Methicillin Resistant Staphylococcus aureus (MRSA). Results indicate that PAM-003 demonstrated visually-appreciable zones of inhibition with a mean value of 8 mm. To further describe the antibacterial activity of the isolate, minimum inhibitory concentration (MIC) of the bacterial extract was determined through broth microdilution technique. Results indicate that PAM-003 demonstrated a MIC of 1000 µg/mL against MRSA. Additional investigation on the bioactivity of Philippine isolates from the genus Pseudoalteromonas isolated from highly diverse regions of the country is a considerable initiative for increasing the pipeline of new molecular entities for drug discovery.
19
Gaysina, D., M. Richards, M. Hotopf, I. Colman, D. Kuh e R. Hardy. "P.8.b.003 Affective symptoms, body mass index and metabolic syndrome: a life course approach". European Neuropsychopharmacology 19 (setembro de 2009): S703. http://dx.doi.org/10.1016/s0924-977x(09)71138-1.
Texto completo da fonte
20
Oswald, P., F. Jurysta, C. Kempenaers, J. Mendlewicz e P. Linkowski. "P.8.a.003 Increased nocturnal motor activity in adults with ADHD: a controlled polysomnographic study". European Neuropsychopharmacology 17 (outubro de 2007): S581. http://dx.doi.org/10.1016/s0924-977x(07)70906-9.
Texto completo da fonte
21
Bantas, Maria Goretty D., Yasinta Yenita Dhiki e Stefanus Notan Tupen. "PENGARUH PERAN ORANG TUA TERHADAP HASIL BELAJAR MATEMATIKA SISWA KELURAHAN TETANDARA KABUPATEN ENDE". JUPIKA: JURNAL PENDIDIKAN MATEMATIKA 5, n.º 1 (31 de março de 2022): 24–30. http://dx.doi.org/10.37478/jupika.v5i1.1720.
Texto completo da fonteResumo:
The goal to be achieved in this research is to see the participation of parents in improving children's learning outcomes in mathematics after the pandemic period ends. The research used is descriptive qualitative, the subjects in this study are junior high school students who live in the RT area. 003, RW. 003 Tetandara Village, Ende Regency with a total of 17 people consisting of 9 students and 8 students from different schools and different parents. The results showed that the role given by parents in the mathematics learning process in the form of providing guidance and direction, providing advice, supervising the learning process, and fulfilling children's facilities as students can improve children's learning outcomes in the online mathematics learning process.
22
Saadah, Saadah. "PENERAPAN METODE DISKUSI UNTUK MENINGKATKAN HASIL BELAJAR MATEMATIKA PADA MATERI MENGGUNAKAN PECAHAN DALAM PEMECAHAN MASALAH SISWA KELAS V SDN 003 TEMBILAHAN KOTA KECAMATAN TEMBILAHAN". Primary: Jurnal Pendidikan Guru Sekolah Dasar 6, n.º 2 (16 de novembro de 2017): 539. http://dx.doi.org/10.33578/jpfkip.v6i2.4543.
Texto completo da fonteResumo:
The low mathematics learning outcomes of grade V students is the background of this study, of 18 only 8 (44.45%) are complete, the average value obtained is 55.83. This study aims to improve the results of mathematics learning by applying the method of discussion. This study is a classroom action research conducted in class V SDN 003 Tembilahan Kota, the subject in this study amounted to 18 students consisting of 15 male students and 3 female students. The study was conducted in two cycles, each consisting of two meetings and one daily test. The results of this study states that after applied the method of discussion of mathematics learning outcomes of students of grade V SDN 003 Tembilahan Kota has increased. This is evidenced by: in prasiklus a thorough student is 8 students with an average score of 55.83, in the cycle I complete student is 16 students with an average value of 80.00. And on the second cycle of completed students is 18 students with an average grade of 88.06.
23
Beeharry, Neil, Sean Landrette, Jeff Grotzke, Sophia Gayle, Marylens Hernandez, Stephanie Halene, Peter R. Young et al. "LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease". Blood 134, Supplement_1 (13 de novembro de 2019): 2664. http://dx.doi.org/10.1182/blood-2019-125770.
Texto completo da fonteResumo:
Acute myeloid leukemia (AML) remains a disease with high unmet medical need. While most patients respond to initial therapy, few are cured, relapse rates are high, and most patients eventually develop life-threatening complications. FLT3-mutant disease is a particularly aggressive subtype. Recent approval of drugs targeting FLT3-mutant disease have improved short-term outcomes but not all patients respond, and duration of response is limited by secondary mutations that impede FLT3 inhibitor (FLT3i) binding (intrinsic factors) and by secreted stromal factors that activate alternative pro-survival pathways (extrinsic factors). Heat-shock protein 90 (HSP90) is a chaperone protein involved in many cellular processes and inhibition of HSP90 can have pleiotropic effects in targeting cancer cells such as degradation of oncoproteins that drive survival and proteins that mediate protective signaling. Here, we describe the nonclinical activity of LAM-003, an orally bioavailable HSP90 inhibitor (HSP90i) under clinical development for AML. To assess the anti-leukemic activity of LAM-003, we tested a panel of AML cell lines and primary AML samples. LAM-003 inhibited proliferation of both FLT3-mutant and wild-type cell lines, with preferential activity against cells harboring FLT3-ITD (geometric mean FLT3-ITD EC50 = 670 nM [n=8] vs FLT3 WT EC50 = 1400 nM [n=16]). Additionally, we observed that LAM-003 was potent in a subset of the FLT3 WT cells. To explore whether LAM-003 was effective against tumors driven by oncoproteins that are client proteins of HSP90, we focused on AML cells harboring FLT3-ITD. We confirmed that LAM-003 reduced cell surface FLT3-ITD expression and downstream signaling in MV-4-11 and MOLM-13 cells, consistent with HSP90i-mediated degradation of FLT3-ITD. In BA/F3 cells expressing FLT3-ITD with various secondary resistance mutations, we observed that LAM-003 elicited a dose-dependent reduction of FLT3 mutant cell surface expression. Moreover, BA/F3 cells expressing FLT3-ITD and the F691L mutation exhibited the expected resistance to crenolanib, yet LAM-003 retained anti-proliferative activity. Additionally, MOLM-13 cells harboring a FLT3 D835Y mutation demonstrated expected resistance to the FLT3i sorafenib and tandutinib yet remained sensitive to LAM-003. Finally, primary AML blasts harboring a D835 mutation displayed sensitivity to LAM-003 when tested ex vivo. To evaluate the potential of LAM-003 to overcome bone-marrow-stroma-derived resistance, FLT3-ITD AML cell lines (MV-4-11, MOLM-13, MOLM-14) were assayed in unconditioned or stromal-cell-conditioned medium. Conditioned medium dramatically reduced the potency of FLT3i but LAM-003 demonstrated equal potency under both conditions. We also showed that stromal cell co-culture induced FLT3i resistance in MOLM-13 cells whereas LAM-003 retained potent activity. Recognizing that the inherent genetic heterogeneity of AML blasts limits the curative potential of a single drug, we performed in vitro studies to identify drugs that synergize with LAM-003 in 3 FLT3-ITD AML cell lines. Synergy was demonstrated with FLT3i, daunorubicin, azacitidine or cytarabine, with the most robust synergy being observed with venetoclax. Extending the evaluation to AML cells wild type for FLT3 and cell lines from other hematologic indications (multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma), we found that the synergy was not limited to cells harboring FLT3-ITD, but rather correlated with BCL-2 abundance, suggesting a fundamental mechanism of action that depends on BCL-2 family-mediated survival. Mechanistic studies demonstrated that the combination of LAM-003 and venetoclax inhibited AKT-mediated regulation of GSK3B, resulting in MCL-1 degradation. In vivo studies using a MOLM-13 systemic model of FLT3-ITD AML demonstrated that LAM-003 monotherapy significantly improved animal survival and that the combination of LAM-003 and venetoclax significantly prolonged animal survival compared with each single agent. These nonclinical studies demonstrate that LAM-003 exhibits antileukemic activity, overcomes mechanisms of FLT3i resistance and potently synergizes with existing AML drugs. As such, our data provide strong rationale for evaluation of LAM-003 in an ongoing clinical trial in patients with AML (NCT03426605). Disclosures Beeharry: AI Therapeutics: Employment, Equity Ownership. Landrette:AI Therapeutics: Employment. Grotzke:AI Therapeutics: Employment. Gayle:AI Therapeutics: Equity Ownership. Young:AI Therapeutics: Employment, Equity Ownership. Miller:Incuron, Inc.: Consultancy; Cleveland Biolabs, Inc: Employment, Equity Ownership; Calistoga Pharmaceuticals, Inc.: Equity Ownership; AI Therapeutics: Consultancy, Equity Ownership; VelosBio Inc.: Employment, Equity Ownership; Acerta Pharma, Inc.: Equity Ownership. Xu:AI Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Rothberg:AI Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Lichenstein:AI Therapeutics: Employment, Equity Ownership.
24
Siregar, Suraidah. "UPAYA MENINGKATKAN HASIL BELAJAR SISWA MELALUI METODE PEMBELAJARAN PROBLEM BASED INSTRUCTION PADA MATA PELAJARAN IPA DI KELAS V SD NEGERI 003 SIHEPENG". JS (JURNAL SEKOLAH) 1, n.º 4 (5 de fevereiro de 2018): 107. http://dx.doi.org/10.24114/js.v1i4.9131.
Texto completo da fonteResumo:
Abstrak : Upaya Meningkatkan Hasil Belajar Siswa Pada Mata Pelajaran Ilmu Pengetahuan Alam Melalui Metode Pembelajaran Problem Based Instruction di Kelas V SD Negeri No. 003 Sihepeng. Subjek penelitian ini adalah siswa Kelas V SD Negeri No. 003 Sihepeng Kecamatan Siabu Kabupaten Mandailing Natal dengan jumlah siswa 18 orang, 8 orang diantara perempuan dan 10 orang laki-laki. Dari penelitian yang dilaksanakan diperoleh peningkatan hasil belajar setelah dilaksanakan tindakan. Pada siklus I diperoleh presentase presentase ketuntasan belajar siswa 61,1% dan skor nilai ketuntasan kelas 62,5% dengan nilai terendah 50 dan nilai terbaik 80. Pada siklus II diperoleh presentase ketuntasan belajar siswa sebesar 100% dan skor nilai ketuntasan kelas 87,7% dengan nilai terendah 70 dan nilai terbaik 90.
Kata Kunci : Problem Based Instruction (PBI), Mata Pelajaran IPA, Aktivitas Siswa, Hasil Belajar
25
Trudel, Suzanne, Susan Lee, Christopher J. Kirk, Nashat Gabrail, Sagar Lonial, Luhua Wang, Robert Z. Orlowski et al. "Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients." Blood 114, n.º 22 (20 de novembro de 2009): 1845. http://dx.doi.org/10.1182/blood.v114.22.1845.1845.
Texto completo da fonteResumo:
Abstract Abstract 1845 Poster Board I-871 Background: Proteasome inhibition is an effective strategy for the treatment of multiple myeloma. In patients, proteasome inhibition has primarily been measured in peripheral blood samples (whole blood or mononuclear cells). However, it is unknown whether myeloma cells in the bone marrow (BM) are equally sensitive to proteasome inhibitors such as bortezomib (BTZ) and carfilzomib (CFZ). Aim: To measure proteasome inhibition in purified tumor cells from BM samples taken from patients enrolled in two ongoing Phase 2 trials of single agent CFZ in relapsed or refractory myeloma: PX-171-003 (003) and PX-171-004 (004). Methods: CFZ was administered as an IV bolus of 20 mg/m2 on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle on both trials. Bone marrow samples, from an optional sub-study of both trials, were taken during screening and Day 2 (post-treatment) and sorted into CD138+ and CD138− cells. Proteasome activity was measured by an enzymatic assay using a fluorogenic substrate (LLVY-AMC) for the chymotrypsin-like (CT-L) activity and an active site ELISA (ProCISE) to quantitate levels of the CT-L subunits of the constitutive proteasome (Beta5) and immunoproteasome (LMP7) and the immunoproteasome subunit MECL1. Results: Whole blood samples from patients treated with CFZ showed inhibition of CT-L activity of ∼80+, similar to values obtained in Phase 1 studies. A total of 10 CD138+ screening samples, 6 from 004 and 4 from 003, and 9 post-dose samples, 5 from 004 and 4 from 003, were analyzed for proteasome levels and activity. In addition, 15 CD138−screening samples, 7 from 004 and 8 from 003, and 9 post-dose samples, 5 from 004 and 4 from 003, were analyzed. When compared to the average base-line activity, CFZ treatment resulted in 88% CT-L inhibition in CD-138+tumor cells from 004 patients (P = 0.0212 by unpaired t-test) and 59% CT-L inhibition in CD-138+ tumor cells from 003 patients (P = 0.25). Baseline CT-L activity in CD138+ tumor cells was 3-fold higher in 004 than 003, which includes a more heavily pre-treated patient population with greater prior exposure to BTZ. Higher specific enzymatic activity was due to increased levels of both constitutive and immunoproteasomes in tumor cells, where immunoproteasomes account for >75% of total cellular proteasomes. No differences between trials were seen in baseline CT-L activity from non-tumor (CD138−) cells. Inhibition in CD138− cells was 84% (P = 0.0380 and 42% (P = 0.38) in 004 and 003, respectively. Using ProCISE, we measured inhibition of LMP7 (66%), beta5 (48%) and MECL1 (64%) in CD138+ tumor cells from 004 patients. Three patients from 004 and one from 003 had both a screening and post-dose tumor cell samples available for analysis. Inhibition of CT-L activity was >80% in two of the 3 patients on 004; the third patient showed no proteasome inhibition by ProCISE and was unavailable for analysis by CT-L. CT-L activity in the CD138+ tumor cells in the 003 patient was not inhibited, however, inhibition was seen in non-tumor cells. Conclusions: CFZ inhibits the proteasome activity of myeloma cells in the bone marrow of relapsed and refractory myeloma patients. The levels of inhibition were similar to those measured in whole blood samples, supporting the use of the blood-based assay as a surrogate marker for proteasome inhibition in tumor cells. CFZ treatment resulted in inhibition of both CT-L subunits as well as additional subunits of the immunoproteasome in tumor cells. Reduced baseline activity in the more heavily pretreated 003 patients may reflect reduced tumor-dependency on the proteasome and may be related to prior treatment with BTZ in these patients. More samples are needed in order to make correlations between levels of proteasome inhibition in bone marrow tumor cells and prior therapies or response. These observations support further evaluation of proteasome activity and the effects of this promising new agent in primary tumors cells from myeloma patients. Disclosures: Trudel: Celgene: Honoraria, Speakers Bureau; Ortho Biotech: Honoraria. Lee:Proteolix, Inc.: Employment. Kirk:Proteolix, Inc.: Employment. Lonial:Celgene: Consultancy; Millennium: Consultancy, Research Funding; BMS: Consultancy; Novartis: Consultancy; Gloucester: Research Funding. Wang:Proteolix, Inc.: Research Funding. Kukreti:Celgene: Honoraria. Stewart:Genzyme, Celgene, Millenium, Proteolix: Honoraria; Takeda, Millenium: Research Funding; Takeda-Millenium, Celgene, Novartis, Amgen: Consultancy. Jagannath:Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. McDonagh:Proteolix: Research Funding. Zonder:Celgene: Speakers Bureau; Pfizer: Consultancy; Seattle Genetics, Inc.: Research Funding; Amgen: Consultancy; Millennium: Research Funding. Bennett:Proteolix: Employment.
26
Rajagopal, Raj, Andrew S. Waller, James D. Mendoza e Paul D. Wightman. "The covalent modification and regulation of TLR8 in HEK-293 cells stimulated with imidazoquinoline agonists". Biochemical Journal 409, n.º 1 (11 de dezembro de 2007): 275–87. http://dx.doi.org/10.1042/bj20070519.
Texto completo da fonteResumo:
The mammalian TLRs (Toll-like receptors) mediate the rapid initial immune response to pathogens through recognition of pathogen-associated molecular patterns. The pathogen pattern to which TLR8 responds is ssRNA (single-stranded RNA) commonly associated with ssRNA viruses. TLR8 also responds to small, purine-like molecules including the imidazoquinoline IRMs (immune-response modifiers). The IRMs include molecules that selectively activate TLR7, selectively activate TLR8 or non-selectively activate both TLR7 and TLR8. Using HEK-293 cells (human embryonic kidney cells) stably expressing an NF-κB (nuclear factor κB)/luciferase promoter-reporter system as a model system, we have examined the regulation of TLR8 using the non-selective TLR7/8 agonist, 3M-003. Using conservative tyrosine to phenylalanine site-directed mutation, we show that of the 13 tyrosine residues resident in the cytosolic domain of TLR8, only three appear to be critical to TLR8 signalling. Two of these, Tyr898 and Tyr904, reside in the Box 1 motif and the third, Tyr1048, lies in a YXXM putative p85-binding motif. TLR8 is tyrosine-phosphorylated following 3M-003 treatment and TLR8 signalling is inhibited by tyrosine kinase inhibitors. Treatment with 3M-003 results in the association of the p85 regulatory subunit of PI3K (phosphoinositide 3-kinase) with TLR8 and this association is inhibited by tyrosine to phenylalanine mutation of either the YXXM or Box 1 motifs. As a further consequence of activation by 3M-003, TLR8 is modified to yield both higher and lower molecular mass species. These species include a monoubiquitinated form as deduced from ubiquitin peptide sequencing by HPLC/MS/MS (tandem MS).
27
Rowe, P. C., W. Walop, H. Lior e A. M. Mackenzie. "Haemolytic anaemia after childhoodEscherichia coliO 157.H7 infection: are females at increased risk?" Epidemiology and Infection 106, n.º 3 (junho de 1991): 523–30. http://dx.doi.org/10.1017/s0950268800067583.
Texto completo da fonteResumo:
SUMMARYWe conducted a 4-year retrospective cohort study to better define the risk of haemolytic anaemia and haemolytic uraemic syndrome (HUS) in children following sporadic gastrointestinal infection with the O 157.H7 serotype ofEscherichia coli. Of the 72 children infected with this organism, 9 (12·5%) developed haemolytic anaemia, 6 of whom had HUS. No child in a cohort of 72 age-matched controls withCampylobacter jejunigastroenteritis developed haemolytic anaemia (P= 0·003). Females had a significantly greater risk of developing haemolytic anaemia afterE. coliO 157.H7 infection than did males (8/29 femalesv.1/43 males;P= 0·003). In a logistic regression model, female gender emerged as the only statistically significant risk factor for haemolytic anaemia (odds ratio 3·85; 95% confidence interval 1·24–12). These results are consistent with recent reports of a moderate increase in the risk of HUS for females.
28
Giagounidis, Aristoteles, Alan F. List, Eva Hellstrom-Lindberg, Ghulam J. Mufti, Brigitte Schlegelberger, John Morrill, Chengqing Wu, Barry Skikne, Pierre Fenaux e Gudrun Göhring. "Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies". Blood 124, n.º 21 (6 de dezembro de 2014): 3270. http://dx.doi.org/10.1182/blood.v124.21.3270.3270.
Texto completo da fonteResumo:
Abstract Introduction: Around 50% of pts with de novo MDS present with chromosomal abnormalities at diagnosis. One of the most common cytogenetic abnormalities in MDS, deletion 5q [del(5q)], occurs in ~15% of pts (Haase et al. Blood 2007;110:4385-95). The presence of cytogenetic abnormalities in addition to del(5q) may be associated with shorter overall survival (OS) and increased risk of progression to acute myeloid leukemia (AML) versus del(5q) alone (Mallo et al. Leukemia 2011;25:110-20). In 2 large multicenter studies (MDS-003 and MDS-004), lenalidomide (LEN) was evaluated in RBC transfusion-dependent pts with IPSS Low/Intermediate (Int)-1-risk MDS and del(5q) (List et al. N Engl J Med 2006;355:1456-65; Fenaux et al. Blood 2011;118:3765-76). This analysis describes the prevalence and clinical impact of the most common cytogenetic abnormalities in pts with del(5q) from MDS-003 and MDS-004. Methods: Of 353 pts enrolled in MDS-003 and MDS-004, 281 pts had available cytogenetic data with ≥ 16 metaphases evaluable, and were included in the analysis. Pts received 10 mg LEN on days 1–21 of each 28-day cycle; LEN 5 mg or 10 mg continuously; or placebo. In MDS-004, placebo pts could crossover to LEN 5 mg by Week (Wk) 16. Centrally reviewed cytogenetic studies were performed at baseline, and wks 24 and 48 (MDS-003); or baseline, Wk 24, and every 24 wks thereafter (MDS-004). RBC-transfusion independence (RBC-TI) ≥ 26 wks, cytogenetic response (CyR), AML progression, and OS were assessed by most common cytogenetic abnormalities in LEN-treated pts with del(5q) plus 1 additional abnormality. Some pts did not fulfill the IPSS lower-risk classification after central pathologic/cytogenetic evaluation. For this analysis outcomes in the del(5q) plus ≥ 2 additional abnormalities group were not evaluated. Results: Of the 281 pts, 70.8% had isolated del(5q), 19.9% del(5q) plus 1 additional abnormality, and 9.3% had del(5q) plus ≥ 2 additional abnormalities. Baseline characteristics including age, time from diagnosis, RBC transfusion burden, hemoglobin level, and platelet and absolute neutrophil counts were comparable across the cytogenetic groups. In pts with del(5q) plus 1 additional abnormality at baseline, the most common numerical abnormalities were +8 (17.9%; n = 10), +21 (14.3%; n = 8), and −7 (3.6%; n = 2); the most common balanced structural rearrangements were translocation 2;11 [t(2;11)] (5.4%; n = 3) and isochromosome 21q [i(21q)] (3.6%; n = 2); and the most common unbalanced structural rearrangements were del(11q) (7.1%; n = 4), del(20q) (5.4%; n = 3), del(9q) (3.6%; n = 2), and del(12p) (3.6%; n = 2) (Figure). In the del(5q) plus 1 additional abnormality group, baseline characteristics were comparable across pts with +8, +21, or other abnormalities (i.e. excluding those with +21 and +8), with the exception of age (P = 0.023). Rates of RBC-TI ≥ 26 wks and CyR did not significantly differ among LEN-treated pts with +8 (n = 9), +21 (n = 8), or other abnormalities (n = 37). Rates of RBC-TI ≥ 26 wks were 66.7%, 50.0%, and 54.1% (P = 0.839), respectively. In pts evaluable for CyR (n = 40), CyR rates were 42.9%, 42.9%, and 65.4% (P = 0.407), respectively. Median time to AML progression was shorter in LEN-treated pts with +21 (2.6 years [yrs]; 95% CI 1.2–4.8) versus +8 (4.8 yrs; 95% CI 1.6–not estimable) or other abnormalities (7.5 yrs; 95% CI 4.1–7.5) (P = 0.0143). The 5-year AML progression rates were 68.8% (95% CI 26.6–98.7), 85.7% (95% CI 53.5–99.3), and 36.3% (95% CI 19.2–61.3) in pts with +8, +21, or other abnormalities, respectively. Median OS was 4.1 yrs (95% CI 0.9–5.3), 3.0 yrs (95% CI 1.1–4.9), and 3.4 yrs (95% CI 2.6–6.5) (P = 0.423), respectively. Of the 2 pts with −7: 1 pt with Int-1-risk MDS had a 92% to 8% reduction of −7-positive metaphases at Day 84 on treatment, but no RBC-TI ≥ 26 wks, and died at Day 709 without AML; the other Int-2-risk pt progressed to AML on Day 147 with clearance of −7 from 8%, and development of new +8 and del(16q) abnormalities. Conclusions:In MDS pts with del(5q) plus 1 additional abnormality from MDS-003 and MDS-004, the most common cytogenetic abnormalities were +8, +21, del(11q), del(20q), and t(2;11), which accounted for 50% of the additional abnormalities at baseline. In the del(5q) plus 1 additional abnormality population, median time to AML progression was shorter in pts with +21 versus either +8 or other abnormalities. Due to small pt numbers, larger prospective analyses are needed to confirm these observations. Figure 1 Figure 1. Disclosures Giagounidis: Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. List:Celgene Corporation: Consultancy. Hellstrom-Lindberg:Celgene: Research Funding. Mufti:Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Schlegelberger:Celgene Corporation: Consultancy. Morrill:Celgene Corporation: Employment, Equity Ownership. Wu:Celgene Corporation: Employment, Equity Ownership. Skikne:Celgene: Employment, Equity Ownership. Fenaux:Novartis: Research Funding; Janssen: Research Funding; Celgene Corporation: Research Funding.
29
Klich, Sebastian, Bogdan Pietraszewski, Matteo Zago, Manuela Galli, Nicola Lovecchio e Adam Kawczyński. "Ultrasonographic and Myotonometric Evaluation of the Shoulder Girdle After an Isokinetic Muscle Fatigue Protocol". Journal of Sport Rehabilitation 29, n.º 8 (1 de novembro de 2020): 1047–52. http://dx.doi.org/10.1123/jsr.2019-0117.
Texto completo da fonteResumo:
Objectives: The aim of the study was to investigate supraspinatus tendon thickness, acromiohumeral distance (AHD), and stiffness/creep measures of the shoulder girdle in overhead asymptomatic athletes in muscle fatigue conditions. Design: Observational, case series study. Setting: Biomechanics and motion analysis lab. Participants: Twenty-four male overhead volleyball (n = 8), handball (n = 8), and tennis (n = 8) athletes. All subjects were without shoulder injury history. Main Outcome Measure: The subjects were tested for supraspinatus tendon thickness (in short and long axis), AHD using ultrasound scans and stiffness/creep of upper trapezius, infraspinatus, anterior and posterior deltoid, and pectoralis major using the myotonometer device before and immediately after a fatigue protocol. Intervention: The fatigue protocol consisted of 3 sets of 32 maximum isokinetic concentric contractions performing shoulder internal and external rotation at isokinetic speed of 120°/s. Results: A significant increase in supraspinatus tendon thickness (both in short and long axis) (P = .045 and P = .01, respectively) and a reduction in AHD (P = .01) were found after an isokinetic protocol. The stiffness increased significantly in upper trapezius (P ≤ .01), infraspinatus (P = .003), posterior deltoid (P = .047), and pectoralis major (P = .01), whereas the creep showed a significant decrement for upper trapezius (P = .001) and infraspinatus (P = .003). Conclusion: The present study has demonstrated the postexercise fatigue in overhead athletes. The increase of stiffness (reduction of muscle creep) and tendon thickness (simultaneous to the reduction of AHD) may indicate rotator cuff overloading as a primary intrinsic tendon pathology process.
30
Kuznetsova, M. "P.8.b.003 Therapist's role of primary health care in the management of patients with mental disorders". European Neuropsychopharmacology 23 (outubro de 2013): S621. http://dx.doi.org/10.1016/s0924-977x(13)70986-6.
Texto completo da fonte
31
Baxter, Nicholas A., Caroline P. Hoch, Jared J. Reid, Daniel J. Scott e Christopher E. Gross. "Use of the Pain Catastrophizing Scale to Predict Other Patient-Reported Outcome Measures Among Plantar Fasciitis and Chronic Ankle Instability Patients". Foot & Ankle Orthopaedics 7, n.º 4 (outubro de 2022): 2473011421S0057. http://dx.doi.org/10.1177/2473011421s00578.
Texto completo da fonteResumo:
Category: Ankle; Hindfoot; Midfoot/Forefoot Introduction/Purpose: The Pain Catastrophizing Scale (PCS) is a measure of how patients emotionally respond to pain. It is composed of three subscales - rumination, magnification, and helplessness - which address intrusive thoughts of pain, expectations of negative outcomes, and inability to cope with pain. The primary purpose of this study is to (1) compare baseline PCS scores with other baseline PROMs in patients with plantar fasciitis (PF) or chronic ankle instability (CAI). Methods: We retrospectively reviewed the records of 201 patients who reported at least one pre-treatment PCS subscore (rumination=200, magnification=199, helplessness=196, total=194) and were diagnosed with PF (n=116) or CAI (n=98) between 2015 and 2020 in a single fellowship-trained foot and ankle surgeon's clinic. Forty-one (20.4%) patients underwent operative treatment by the primary surgeon and 29 (14.4%) were treated operatively prior to being seen by the primary surgeon. Demographics, comorbidities, treatments, other baseline patient-reported outcome measures (PROMs) (e.g., Visual Analogue Scale [VAS], Pain Disability Index [PDI], 12-Item Short Form Survey [SF-12], 8-Item Somatic Symptom Scale-8 [SSS-8]), and postoperative outcomes were recorded. The average follow-up was 183.92 (range, 0-1,820) days, while the average follow-up duration for the patients treated operatively was 190.56 (range, 15-468) days. Results: The PCS total score and its subscores significantly correlated with the total score and/or subscores of each PROM. Higher PCS total score significantly correlated with worse VAS (p<.001), SF-12 mental (p=.007), PDI total (p<.001), and SSS-8 (p<.001). Only the PCS magnification subscore was significantly greater among patients who did (n=41) undergo surgery (p=.043). Those who had previously undergone foot and/or ankle surgery had significantly higher PCS rumination (p=.012), magnification (p=.006), helplessness (p=.008), and total (p=.003) scores. Likewise, those with a history of substance abuse also had significantly higher PCS scores (p=.005; p=.003; p=.006; p=.003). Conclusion: Significant correlations between PCS scores and other baseline PROMs indicate that strong pain catastrophizers with PF or CAI could be at risk for poor treatment outcomes. PCS scores could be used to tailor treatments for such high-risk patients, as there is evidence regarding the positive impact of cognitive behavior therapy on high pain catastrophizers.
32
ZAVITSANOU, A., M. MALLIORI, V. SYPSA, M. PETRODASKALAKI, M. PSICHOGIOU, C. ROKKA, A. GIANNOPOULOS, V. KALAPOTHAKI, D. WHITBY e A. HATZAKIS. "Seroepidemiology of human herpesvirus 8 (HHV-8) infection in injecting drug users". Epidemiology and Infection 138, n.º 3 (24 de agosto de 2009): 403–8. http://dx.doi.org/10.1017/s0950268809990628.
Texto completo da fonteResumo:
SUMMARYA cross-sectional study was carried out in injecting drug users (IDUs) from Greece to assess the seroprevalence of human herpesvirus 8 (HHV-8) and to identify potentially associated risk factors. A total of 288 IDUs were tested for K8.1 antibodies to HHV-8 lytic antigen. Associations between HHV-8 serostatus and potential risk factors were examined using univariate and multivariate logistic regression analysis. Seroprevalence of HHV-8 was 24·3% (95% CI 19·5–29·7), increasing with age from 19·4% in those aged <30 years to 52·9% in those aged ⩾40 years (Pfor trend=0·003). No statistically significant associations between HHV-8-positive status and gender, educational level, age at first drug injection, needle sharing, number of imprisonments, complications from drug overdose, HIV and HCV were observed. In the multivariate logistic regression analysis, older age (⩾40vs. <40 years, OR 3·30, 95% CI 1·14–9·56) and report of septicaemia/abscess (yesvs. no, OR 1·80, 95% CI 1·01–3·18) were each independently associated with higher HHV-8 seroprevalence. HHV-8 is highly prevalent in the IDU population in Greece. The independent association between HHV-8 and reported abscess or septicaemia supports the hypothesis that poor hygiene conditions in the setting of drug injection may contribute to HHV-8 transmission.
33
Harvey, R. Donald, Sagar Lonial, Priti Patel, Leanne McCulloch, Ruben Niesvizky e Jonathan L. Kaufman. "Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): e18569-e18569. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18569.
Texto completo da fonteResumo:
e18569 Background: Patients (pts) with multiple myeloma (MM) are vulnerable to renal injury and impairment both from their disease and treatment-related adverse events (AEs). Carfilzomib (CFZ) is a selective proteasome inhibitor with proven efficacy in MM. Safety data have been compiled from over 700 pts who have received single-agent CFZ. All were pretreated and included individuals with varying degrees of renal function, including hemodialysis pts. Herein we present an analysis of the incidence and severity of CFZ treatment-emergent renal events from 526 pts in four phase 2 trials. Methods: Pts from the 003-A0, 003-A1, 004, and 005 trials were included in this analysis. In all studies, CFZ was dosed on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle (C). Doses were 20 mg/m2 in C1 for all studies escalating to 27 mg/m2 in C2 per individual protocol, except 005 (15 mg/m2 in C1, 20 mg/m2 in C2, and 27 mg/m2 in C3). Renal AEs—the incidence, frequency, and resolution of episodes of worsening renal function, defined minimally as a doubling of serum creatinine from baseline—and shifts in other laboratory parameters were tabulated and summarized based on NCI CTCAE v.3 criteria. Results: The majority of pts (71%) had renal dysfunction (CrCl <50 mL/min) at baseline. Overall, 87% experienced no significant worsening of renal function during the course of treatment. Transient worsening was reported in 31 pts (6%) with a median duration of 1.4 weeks and a median of 1.0 episode per patient; non-transient worsening was reported in 37 pts (7%) with 8 (2%) of those permanently discontinuing treatment due to a renal dysfunction AE. 38 patients (7.2%) experienced Grade 3/4 acute renal failure, of which 31 were Grade 3. The percentage of patients in 003-A0, 003-A1, and 004 whose creatinine levels shifted to Grade 3 or 4 from any lower grade was <5%. Results from 005 showed no major PK differences in pts with a wide range of renal function. Conclusions: Treatment-emergent renal events resulting in CFZ discontinuation were uncommon. Based on the findings from this cross trial analysis, CFZ dose and schedule need not be adjusted in pts with baseline renal dysfunction, including pts on hemodialysis.
34
Banfield, Stephen. "Bill Marshall and Robynn Stilwell, ed. Musicals: Hollywood and BeyondExter: Interllect Books, 2000. £14.95. ISBN: 1-84150-003-8." New Theatre Quarterly 17, n.º 4 (novembro de 2001): 396. http://dx.doi.org/10.1017/s0266464x00015050.
Texto completo da fonte
35
Mar, J., J. Vivancos, J. Rejas, A. Arrospide e J. Caro. "P.8.a.003 Clinical and cost-effectiveness analysis of using atorvastatin for secondary stroke prevention: a Spanish perspective". European Neuropsychopharmacology 19 (setembro de 2009): S695. http://dx.doi.org/10.1016/s0924-977x(09)71124-1.
Texto completo da fonte
36
Stuhec, M. "P.8.b.003 Pharmacotherapy review as a safety and cost tool in patients management in Slovenian Psychiatric Hospital". European Neuropsychopharmacology 24 (outubro de 2014): S735—S736. http://dx.doi.org/10.1016/s0924-977x(14)71185-x.
Texto completo da fonte
37
Uemura, Shun, Masayuki Yamashita, Ayako Aihara, Takumi Iwawaki, Shuhei Koide, Yaeko Nakajima-Takagi, Motohiko Oshima et al. "YAP/TAZ Promote Hematopoietic Regeneration Via Accelerating the Recovery of Bone Marrow Niche". Blood 138, Supplement 1 (5 de novembro de 2021): 199. http://dx.doi.org/10.1182/blood-2021-148212.
Texto completo da fonteResumo:
Abstract Adult hematopoietic stem cells (HSCs) reside and are protected in a unique bone marrow (BM) microenvironment, termed the HSC niche, which consists mainly of vascular endothelial cells (EC) and EC-associated mesenchymal stromal cells (MSC). Myeloablative stresses, such as ionizing radiation (IR) and chemotherapy, induce not only depletion of hematopoietic cells but also disruption of HSC niche components, as exemplified by dilation and leakiness of BM vasculature and depletion and dysfunction of BM MSCs. These structural and functional changes in the HSC niche restrain efficient hematopoietic recovery, which often compromises the efficacy of HSC transplantation (HSCT) and chemotherapy. YAP/TAZ are the two transcriptional coactivators normally repressed by LATS kinases downstream of the Hippo pathway. Although cumulative evidence has established a critical role of YAP/TAZ activation in tissue regeneration of various solid organs, their role in BM regeneration remains poorly understood. Our quantitive RT-PCR revealed that YAP/TAZ are abundantly expressed in steady-state mouse ECs (CD45 -Ter119 -CD31 +Sca1 +CD105 hi) and MSCs (CD45 -Ter119 -CD31 -PDGFRα +CD51 +LepR +) but scarcely in hematopoietic cells including HSCs (Lin -cKit +Sca1 +Flk2 -CD150 +CD48 -CD34 lo), which was confirmed by reanalysis of the published single cell RNA-seq datasets (GSE128423). Immunofluorescent imaging of BM sections revealed that YAP/TAZ are distributed mainly in the cytoplasm of ECs but evenly in the cytoplasm and nuclei of MSCs, indicating their differential basal activity in these two HSC niche components. Kinetic transcriptome analysis revealed that YAP/TAZ activity is transiently activated in ECs at 24 hours and returns to a basal repressive state by day 3 after sublethal IR. This transient activation of endothelial YAP/TAZ was critical for vascular integrity, as conditional deletion of YAP/TAZ in ECs (Cdh5-Cre ERT2Yap1 f/fTaz f/f) caused 100% lethality of mice within 10 days following sublethal IR. In sharp contrast, the kinetic expression analysis of a YAP/TAZ target gene CTGF indicated their transient inhibition in MSCs after sublethal IR, and the conditional YAP/TAZ deletion in BM MSCs (Ebf3-Cre ERT2Yap1 f/fTaz f/f) led to their reduced colony forming ability when assessed by colony forming unit fibroblast (CFU-F) assay. Recently, we discovered a novel and potent LATS inhibitor GA-003 that selectively induces mouse and human YAP/TAZ activation in vitro (IC 50 against LATS1 = 1.06 ± 0.08 nM). To analyze the effect of pharmacological YAP/TAZ activation on BM regeneration in vivo, we treated mice with intraperitoneal injection of GA-003 (50 mg/kg per day, for 8 days) following sublethal IR. Remarkably, we observed an accelerated recovery of hematopoiesis, with the absolute numbers of BM cellularity, GMP (Lin -cKit +Sca1 -FcγR +CD34 +) and HSC EPCR (Lin -cKit +Sca1 +CD150 +EPCR +) on day 14 increased by 3.50-fold (p=0.0002), 6.49-fold (p=0.0022) and 11.41-fold (p=0.022), respectively in the GA-003-treated group compared to vehicle-treated group. In addition, GA-003 also promoted hematopoietic recovery after 5-FU injection (150 mg/kg) and HSCT. Nonetheless, consistent with the scarce expression of YAP/TAZ in hematopoietic stem and progenitor cells (HSPC), in vitro GA-003 treatment did not enhance HSPC growth, suggesting niche-mediated effects by GA-003. Indeed, in vitro tube formation assay indicated accelerated angiogenesis by GA-003-treated human umbilical vein ECs, and CFU-F assays revealed significant enhancement of colony formation by mouse BM-derived MSCs upon GA-003 treatment. To reveal the effect of GA-003 on the HSC niche components in vivo, we performed whole BM immunofluorescent imaging at various time points following sublethal IR and GA-003 treatment. We observed alleviated vascular dilation and leakiness and earlier restoration of vascular damage in GA-003-treated group compared to vehicle-treated group, which was associated with increased VE-Cadherin expression in ECs. These results suggest that reinforcing YAP/TAZ activity upon myelosuppression promotes HSC niche integrity and recovery and accelerates hematopoietic regeneration. Taken together, our results establish YAP/TAZ as novel regulators of HSC niche and highlight YAP/TAZ as promising therapeutic targets to boost hematopoietic recovery after myeloablative interventions such as chemotherapy and HSCT. Disclosures Aihara: Nissan Chemical Corporation: Current Employment. Iwawaki: Nissan Chemical Corporation: Current Employment. Nishino: Nissan Chemical Corporation: Current Employment. Iwama: Nissan Chemical Corporation: Research Funding.
38
Hidayati, Nurlisa, Neza Rahayu Palapa, Bakri Rio Rahayu, Risfidian Mohadi, Elfita Elfita e Aldes Lesbani. "Citrate-Zn/Al Layered Double Hydroxide as Adsorbent of Congo Red from Aqueous Solution". Mediterranean Journal of Chemistry 10, n.º 3 (13 de março de 2020): 220–32. http://dx.doi.org/10.13171/mjc02003131281al.
Texto completo da fonteResumo:
Layered double hydroxide (LDH) of Zn/Al and citrate-Zn/Al was prepared and used as an adsorbent of Congo red from aqueous solution. LDH was characterized by X-ray, FTIR, and BET analysis. Adsorption of Congo red was studied through kinetic, isotherm, and thermodynamic analyses. Zn/Al LDH has diffraction at 10.29o (003) with interlayer distance 8.59 Å and citrate-Zn/Al LDHs have anomalous diffraction at 7.57o (003) with interlayer distance 11.68 Å. The surface area of citrate-Zn/Al (40.50 m2 g-1) has higher than pristine LDH (1.97 m2 g-1). Adsorption of Congo red was conducted at pH 6 for Zn/Al LDH and at pH 8 for citrate-Zn/Al LDH. Adsorption of Congo red on both LDHs follows the pseudo-second-order kinetic model. The isotherm parameter follows the Freundlich isotherm model with maximum adsorption capacity 166.67 mg g-1 for Zn/Al and 249.99 mg g-1 for citrate-Zn/Al LDH. Adsorption of Congo red on both LDHs was classified as physical adsorption with energy 4.085-4.148 kJ mol-1.
39
Vij, Ravi, Michael Wang, Sundar Jagannath, Ruben Niesvizky, Andrzej J. Jakubowiak, Edward Kavalerchik, Mei Huang e David S. Siegel. "Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma". Blood 122, n.º 21 (15 de novembro de 2013): 1965. http://dx.doi.org/10.1182/blood.v122.21.1965.1965.
Texto completo da fonteResumo:
Abstract Introduction In patients (pts) receiving novel anti-multiple myeloma (MM) therapy, an early marker of response would be useful for predicting patient outcomes. Markers in blood with a short half-life, such as serum free light chain (sFLC), may have the potential to be predictive of early response to treatment. Herein, we report results from a retrospective analysis evaluating the relationship of a reduction in sFLC to best overall response (OR) and progression-free survival (PFS) from 2 phase 2 studies of single-agent carfilzomib (CFZ) in pts with relapsed and/or refractory MM (R/RRMM) (PX-171-003-A1 [003; NCT00511238], median 5 [range 1–20] prior therapies; PX-171-004 [004; NCT00530816], median 2 [range 1–3] prior therapies) and a phase 1/2 study of CFZ, lenalidomide (LEN), and dexamethasone (DEX) (CRd) in pts with relapsed or progressive MM (PX-171-006 [006; NCT00603447], median 2 [range 1–5] prior therapies). Methods Pts in the 003 and 004 studies received CFZ on days (d) 1, 2, 8, 9, 15, and 16 in 28-day cycles. Pts in the 003 study received CFZ at a starting dose of 20 mg/m2 in cycle 1; pts had their dose escalated to a target dose of 27 mg/m2 thereafter for up to 12 cycles. The 004 study included bortezomib (BTZ)-naive and BTZ-treated pts; pts received either CFZ 20 mg/m2 during all cycles or a starting dose of 20 mg/m2 during cycle 1 and a target dose of 27 mg/m2 thereafter. Pts in 006 received CRd in 28-day cycles—CFZ (15–27 mg/m2) on d1, 2, 8, 9, 15, 16; LEN (10–25 mg) orally d1–21; and weekly DEX (40 mg). Responses were assessed by IMWG criteria with minimal response per EBMT criteria on d15 of cycle 1, d1 of cycles 2–12, and at the end of the study. Pts with measurable disease by serum or urine protein electrophoresis were included; pts with disease measurable only by sFLC assay were excluded. An analysis of longitudinal changes in the difference between involved and uninvolved sFLC levels before first evidence of a very good partial response (VGPR) was conducted in pts with k/l <0.26 or >1.65 and involved sFLC ≥50 mg/L. sFLC changes were evaluated using 2 mixed linear models (single-agent: 003 and 004; combination: 006): best OR (≥VGPR vs <VGPR) and time points (d15, 29, 57 of therapy) were the covariates in model 1; PFS (≤6 months, >6 months) and time points (d15, 29, 57) were the covariates in model 2. Correlation between sFLC reduction at d15 and best OR was evaluated using a chi-squared test. Reported P values are 2-sided and with no multiplicity adjustment. Results A total of 221 out of 503 enrolled pts were included in the sFLC analysis. Of these 221 pts, 160 had their sFLC measured at d15. When sFLC changes were assessed in model 1, pts achieving ≥VGPR had greater decreases in sFLC at d15 vs baseline (BL) compared with pts whose best response was <VGPR in both the 003 and 004 populations (P<.0001) and the 006 population (P<.0001). In model 2, pts with PFS >6 months had greater decreases in sFLC from BL vs pts with PFS ≤6 months in 003 and 004 (P<.0001). Pts with PFS >6 months had greater decreases in sFLC from BL vs pts with PFS ≤6 months in 006 study; this change was not significant (P=.1859). Results in Table 1 showed that sFLC decreased significantly more in pts with best OR ≥VGPR than in those with best OR <VGPR at d57 (003), d15 (004) and d15, d29 and d57 (006). In 003, 004, and 006, significantly more pts with a ≥75% reduction in sFLC from BL to d15 achieved ≥VGPR (17/30 [57%]) compared with pts with <75% reduction from BL to d15 (8/130 [6%]; P<.0001) (Table 2). Findings were similar whether pts received single-agent CFZ (003 and 004, P<.0001) or CRd (006, P=.0127). When study groups were compared (003 and 004 vs 006), a significantly greater proportion of pts treated with CRd achieved a ≥75% reduction in sFLC from BL to d15 compared with pts who were treated with single-agent CFZ (45% vs 10%; P<.0001) (Table 3). Conclusions Findings from this retrospective analysis indicate that pts with R/RRMM who are treated with either single-agent CFZ (003, 004) or CRd combination therapy (006), and who exhibit rapid reduction of sFLC levels by d15 of therapy, show a greater predilection for achieving a best response of VGPR or better. A decrease of ≥75% in sFLC from BL on d15 may be associated with increased response (as measured by best OR ≥VGPR) and is more common with CRd than single-agent CFZ. The findings from this analysis—specifically the association of a decline in sFLC at d15—merit further exploration in additional CFZ studies. Disclosures: Vij: BMS: Honoraria; Lilly: Honoraria; Celgene: Research Funding, Speakers Bureau; Onyx: Research Funding, Speakers Bureau; Millenium: Speakers Bureau. Off Label Use: Carfilzomib is a selective proteasome inhibitor that is approved in the US for the treatment of relapsed and refractory multiple myeloma. Wang:Novartis: Research Funding; Janssen: Research Funding; Pharmacyclics: Research Funding; Millennium: Research Funding; Celgene: Honoraria, Research Funding; Onyx: Honoraria, Research Funding. Jagannath:Millennium: Honoraria; Celgene: Honoraria; Onyx Pharmaceuticals: Honoraria; Merck: Honoraria; Ortho Biotech: Membership on an entity’s Board of Directors or advisory committees; Imedex: Membership on an entity’s Board of Directors or advisory committees; Medicom WorldWide: Membership on an entity’s Board of Directors or advisory committees; OptumHealth Education: Membership on an entity’s Board of Directors or advisory committees; PER Group: Membership on an entity’s Board of Directors or advisory committees. Niesvizky:Onyx: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Millennium: The Takeda Oncology Company: Consultancy, Honoraria, Research Funding, Speakers Bureau. Jakubowiak:Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Millennium: Consultancy, Honoraria, Research Funding; Onyx: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Research Funding; Janssen-Silag: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding. Kavalerchik:Onyx: Employment, Equity Ownership. Huang:Onyx: Employment, Equity Ownership. Siegel:Celgene Corporation: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Millennium: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
40
Tinkle, Amanda, Mark Wilson, Jerry Torrison, Michael Parsley, Kylee Dubertstein, Michael Azain e C. Robert Dove. "Comparison of blunt versus functional claw trimming effects on sow gait". Journal of Swine Health and Production 28, n.º 3 (1 de maio de 2020): 118–23. http://dx.doi.org/10.54846/jshap/1143.
Texto completo da fonteResumo:
Objective: To determine the effect of functional claw trimming versus blunt claw trimming on the gait of sows. Materials and methods: Nineteen sows (PIC C29) were transported to the research center and claws were trimmed 3 times over an 8-day period. Dewclaws were trimmed even with the coronary band of the hoof on day 1. Claws were blunt trimmed on day 4 and functional trimming occurred on day 8. The gait of each sow was recorded prior to each trimming to compare the effect of the previous trimming. A final gait recording was taken on day 12. The gait data collected from the sows was compared across days to determine if any changes occurred. Results: Positive improvements in gait data were noted after dewclaw trimming. Changes were seen in velocity (P = .03), stride length (P = .02), stride duration (P = .04), stance (P = .04), and rear percent stance (P = .03). Blunt trimming offset the improvement gained by trimming dewclaws, seen in the changes to rear percent stance (P = .02) and front swing (P = .04). Functional trimming increased the improvement observed by trimming dewclaws. Changes were seen in the stance (P < .001), percent stance (P < .001), stride duration (P = .003), stride length (P = .008), and velocity (P = .003). Implications: Trimming dewclaws and functionally trimming claws improved the sow’s gait. Blunt trimming did not provide the same benefits observed by trimming dewclaws or functionally trimming the claws.
41
Barbeito, S., P. Vega, S. Ruiz de Azua, M. Martínez Cengotitabengoa, B. García, M. Gutiérrez e A. González Pinto. "P.3.e.003 Involuntary admission of first-episode psychotic patients and evolution up to 8 years of follow up". European Neuropsychopharmacology 22 (outubro de 2012): S351—S352. http://dx.doi.org/10.1016/s0924-977x(12)70543-6.
Texto completo da fonte
42
Kuzmik, Ashley, Barbara Resnick e Marie Boltz. "Physical Activity in Hospitalized Persons With Dementia: Feasibility and Validity of the Motionwatch 8". Innovation in Aging 4, Supplement_1 (1 de dezembro de 2020): 763. http://dx.doi.org/10.1093/geroni/igaa057.2753.
Texto completo da fonteResumo:
Abstract Interventions to prevent functional decline in hospitalized persons with dementia (PWD) require objective measures of physical activity (PA). This secondary analysis described PA using MotionWatch 8 actigraphy and considered the feasibility and validity of the MotionWatch 8 in hospitalized PWD. In the first 320 PWD enrolled in the Fam-FFC study, 261 agreed to wear a MotionWatch for 24 hours within 48 hours of admission. Minutes were recorded in sedentary ( x̄ =1767.35, SD= 1327.43), low (x̄ = 202.52, SD=127.78), moderate (x̄ =7.93, SD=25.80 ), and vigorous activity ( x̄ = .85, SD=4.50). Controlling for age, gender, race and comorbidity, counts of activity were significantly associated with ADL function (t =4.3, p <.001). Sedentary (t =-3.9, p<.001), low (t =2.8, p =.006), and moderate (t =3.0, p =.003) activity, but not vigorous activity were significantly associated with ADL function. MotionWatch 8 appears feasible and valid when evaluating PA among hospitalized PWD.
43
Raade, Gunnar, C. J. Elliott e V. K. Din. "New data on glaucocerinite". Mineralogical Magazine 49, n.º 353 (setembro de 1985): 583–90. http://dx.doi.org/10.1180/minmag.1985.049.353.13.
Texto completo da fonteResumo:
AbstractThe strongest lines in the X-ray powder diffraction pattern of type material of glaucocerinite from Laurion (Greece), indexed on a hexagonal pseudocell, are 10.9 (100) (003), 5.45 (90) (006), 3.63 (80) (009), 2.62 (60) (012), 2.46 (60) (015), 2.231 (50) (018), and 1.981 Å (50) (0.1.11). The pseudocell parameters area3.0700(8),c32.65(1) Å. Chemical analysis of topotype material yields the formula [(Zn,Cu)5Al3(OH)16] [(SO4)1.5·9H2O] based on a pyroaurite-like structure. The pseudocell parameters for this sample area3.057(3),c32.52(5) Å. Optical data are 2Vα⋍ 60°,α1.540,β1.554,γ1.562;D(meas.) = 2.4±0.1 g/cm3,D(calc.) = 2.33 g/cm3. So-called ‘woodwardite’ from Caernarvonshire, Wales, is identified as the Cuanalogue of glaucocerinite. An ‘11 Å mineral’ occurring together with carrboydite in Western Australia is shown to be the Ni-analogue of glaucocerinite. Alleged cotype glaucocerinite from Laurion is related to woodwardite and has the formula [(Zn,Cu)2Al(OH)6][(SO4)0.5· 3H2O]. This is a cation-ordered pyroaurite-type structure with hexagonal cell parametersa5.306(2),c26.77(2) Å. The strongest X-ray powder lines occur at 8.9 (100) (003), 4.47 (90) (006), 2.55 (60) (113), and 2.28 Å (50) (116).
44
Ye, Le-chi, Yunshi Zhong, Tianshu Liu, Ye Wei, Li Ren, Dexiang Zhu, Xinyu Qin et al. "Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): 3610. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3610.
Texto completo da fonteResumo:
3610 Background: Recently, early tumor shrinkage (ETS) was reported to predict outcome in metastatic colorectal cancer treated with cetuximab (cet). This study was to evaluate the impact of ETS on long-term outcome in patients (pts) with wild-type-KRAS unresectable CLLM receiving cet plus chemotherapy (CT, FOLFIRI or mFOLFOX6). Methods: 138 pts treated in a randomized controlled trial (70 in armA received CT plus cet and 68 in armB received CT alone) previously reported (Jianmin et al, ESMO 2012, abstract-557, ClinicalTrials.gov, number NCT01564810) were included into this analysis. ETS was defined as a reduction of ≥20% in the sum of the longest diameters of target lesions compared to baseline at the first evaluation (8 weeks). Outcome measures were progression-free survival (PFS) and overall survival (OS). Results: 132 pts were available for evaluation, and ETS occurred more frequently in armA than that in armB (45/68 vs. 26/64, p= .003). Irrespective of treatment arm, pts achieved ETS were associated with longer OS (armA: 38.0 vs. 18.7months, p< .001; armB 30.6 vs.17.7months, p= .003) and PFS (armA: 11.8 vs. 4.8months, p< .001; armB 8.0 vs.4.6months, p= .001) when compared to pts with no-ETS. Among pts with ETS, there were statistic difference between armA and armB in terms of PFS (11.8 vs. 8.0months, p= .041) but not of OS (38.0 vs. 30.6months, p= .30); the converted resection rates for liver metastases were 40.0% (18/45) in armA and 19.2% (5/26) in armB, which were no significantly different (p= .072). For pts without liver surgery, pts observed ETS also gained an increased survival benefit over those no-ETS in armA with regards to OS (p= .01) and PFS (p< .001) though it was not full certified in armB (OS: p= .054; PFS: p= .041). For pts in armA, cet-induced skin toxicity correlated with the occurrence of ETS (p= .048). In addition, cox regression for OS using indicated a hazard ratio of 0.39 (95%CI 0.21–0.72, p = .003). Conclusions: ETS ≥20% at 8 weeks may serve as a predictor of favorable outcome in pts with wild-type-KRAS CLLM receiving cet plus CT.
45
Larouche, Danielle, Mirette Hanna, Sue-Ling Chang, Simon Jacob, Bernard Têtu e Caroline Diorio. "Evaluation of Antioxidant Intakes in Relation to Inflammatory Markers Expression Within the Normal Breast Tissue of Breast Cancer Patients". Integrative Cancer Therapies 16, n.º 4 (30 de novembro de 2016): 485–95. http://dx.doi.org/10.1177/1534735416676584.
Texto completo da fonteResumo:
Chronic inflammation may be a causative factor in breast cancer. One possible underlying mechanism is the generation of oxidative stress, which may favor tumorigenic processes. Antioxidant consumption may, therefore, help reduce tissue inflammation levels. However, few studies have explored this relation in breast tissue. We aimed to evaluate correlations between antioxidant (vitamin A/retinol, vitamin C, vitamin E, β-carotene, α-carotene, lycopene, lutein/zeaxanthin, β-cryptoxanthin, selenium, and zinc) intakes and protein expression levels of interleukin (IL)-6, tumor necrosis factor-α, C-reactive protein, cyclooxygenase-2, leptin, serum amyloid A1, signal transducer and activator of transcription 3, IL-8, IL-10, lactoferrin, and transforming growth factor-β measured in the normal breast tissue of 160 women diagnosed with breast cancer. Antioxidant intakes were collected using a self-administered food frequency questionnaire. Inflammation marker expression was assessed by immunohistochemistry. Correlations between antioxidant intakes and inflammatory marker expression were evaluated using Spearman’s partial correlation coefficients ( r) for all women and for premenopausal and postmenopausal women separately. After Bonferroni correction, negative correlations were observed between dietary β-tocopherol and IL-10 expression in all women combined ( r = −0.26, P = .003) and among postmenopausal women ( r = −0.39, P = .003). For all women, a negative correlation was found between total zinc intakes and IL-10 ( r = −0.26, P = .002). Among postmenopausal women, dietary selenium intake was negatively correlated with the expression of lactoferrin ( r = −0.39, P = .003). No associations were observed in premenopausal women. Our findings suggest that consumption of specific antioxidants, including β-tocopherol, zinc, and selenium, may act on the breast tissue through mechanisms affecting the expression of some inflammation markers, particularly among postmenopausal women.
46
Polo-Morales, Aranza, Ángel Alcocer-Salas, Mayela Rodríguez-Violante, Daniella Pinto-Solís, Rodolfo Solís-Vivanco e Amin Cervantes-Arriaga. "Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease". Journal of Geriatric Psychiatry and Neurology 34, n.º 1 (6 de fevereiro de 2020): 60–65. http://dx.doi.org/10.1177/0891988720901787.
Texto completo da fonteResumo:
Objective: To assess the frequency of somatization and its association with motor, nonmotor symptoms, and quality of life in persons with Parkinson disease (PD). Methods: A cross-sectional case–control study was carried out. Assessments included the List of 90 Symptoms somatic factor (SCL-90-R SOM), Movement Disorder Society Unified Parkinson’s Ratings Scale (MDS-UPDRS), Non-Motor Symptom Scale (NMSS), Montreal Cognitive Assessment (MoCA), and Parkinson Questionnaire-8 (PDQ-8). Results: A total 93 persons with PD and 93 controls were included. Somatization within the PD group was 2 times more frequent compared to the control group (43% vs 21.5%, P = .003). Persons with PD had higher NMSS total scores (48.6 ± 42.6 vs 28.3 ± 30.4, P = .001). Patients with PD with somatization had worst MDS-UPDRS, NMSS, MoCA, and PDQ-8 (all P < .05). Conclusion: Somatization is more frequent in persons with PD compared to healthy controls. Somatization in PD is associated with nonmotor symptoms and worst quality of life.
47
Rosa Guillamón, Andres, Eliseo Garcia Canto e Pedro Jose Carrillo López. "Actividad física, condición física y autoconcepto en escolares de 8 a 12 años (Physical activity, physical fitness and self-concept in schoolchildren aged between 8 to 12 years old)". Retos, n.º 35 (16 de outubro de 2018): 236–41. http://dx.doi.org/10.47197/retos.v0i35.64083.
Texto completo da fonteResumo:
Este artículo analizó la relación entre actividad física, condición física y autoconcepto. Un total de 103 escolares (8-12 años) participaron en la evaluación de dichas variables. La condición física se valoró mediante diversas pruebas de la Batería ALPHA-Fitness, el nivel de actividad física se calculó a través del cuestionario PACE y el autoconcepto se midió utilizando la Escala de Autoconcepto de Piers-Harris. Las pruebas estadísticas fueron: T-student, U de Mann-Whitney y Krustal-Wallis. Aquellos físicamente activos tuvieron mejores registros en las dimensiones conductual, intelectual, falta de ansiedad y global. Aquellos con mayor condición física mostraron un mejor autoconcepto físico (p = .013), social (p = .003) y global (p = .085). Aquellos físicamente activos y con mayor condición física tuvieron un mejor autoconcepto intelectual (p = .007), social (p = .010) y global (p = .010). Ser físicamente activo y tener un mayor nivel de condición física podría predecir un autoconcepto más positivo en escolares de la Región de Murcia.Abstract. This article analized the relationship between physical activity, physical condition and self-concept. A total of 103 schoolchildren (8-12 years old) participated in the assessment of these variables. Physical fitness was assessed through various tests from the ALPHA-Fitness Battery, level of physical activity was calculated through the PACE questionnaire, and self-concept was measured using the Piers-Harris Self-concept Scale. T-student, Mann-Whitney U, and Krustal-Wallis were employed for statistical analysis. Those who were physically active had better values in behavioral and intellectual domains of self-concept, as well as in lack of anxiety, and global self-concept. Those with greater physical fitness showed a better physical (p = .013), social (p = .003) and global (p = .085) self-concept. Those physically active with greater physical fitness had a better intellectual (p = .007), social (p = .010) and global (p = .010) self-concept. Being physically active and having a higher level of fitness could predict a more positive self-concept in schoolchildren of Murcia (Spain).
48
Siegel, David Samuel DiCapua, Thomas Martin, Seema Singhal, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sundar Jagannath et al. "Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): 8035. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8035.
Texto completo da fonteResumo:
8035 Background: Patients (pts) with relapsed and refractory multiple myeloma (RR MM) who are refractory or intolerant to both bortezomib (BTZ) and immunomodulators (IMiDs; thalidomide [Thal] or lenalidomide [Len]) (ie, “double-refractory/intolerant”), have few therapeutic options and a poor prognosis. Carfilzomib (CFZ), a next generation proteasome inhibitor (PI), has shown durable single-agent activity in clinical studies including 003-A1, an open-label, single-arm phase 2b trial in RR MM. The present analysis describes clinical activity in pts from 003-A1 with double-refractory/intolerant disease and in other groups of clinical interest including pts with disease refractory to all 5 approved classes of anti-MM tx (alkylators, anthracyclines, corticosteroids, IMiDs, and PIs) in clinical use (“refractory to all approved tx”). Methods: Pts from 003-A1 with double-refractory/intolerant disease were analyzed, as were pts with disease refractory to all approved tx. CFZ was given on days 1, 2, 8, 9, 15, 16 of 28-day cycles (C), (20 mg/m2 in C1; 27 mg/m2 in C2–12). Primary endpoint was overall response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival, and safety. Results: The study ORR was 22.9% with median DOR of 7.8 mo (N=266). 228 pts (86%) with double-refractory/intolerant disease had ORRs of 20.6% and a median DOR of 7.4 mo. Conclusions: Single-agent CFZ demonstrated clinically meaningful, durable responses in pts with double-refractory/intolerant MM or disease refractory to all 5 approved classes of tx. The ORRs across groups of clinical interest were generally consistent with results for the entire study population. These results are notable for a next-generation PI and demonstrate the activity of single-agent CFZ in pts with advanced stage MM. [Table: see text]
49
Jenkins, A. P., A. Guldeste, M. J. Goringe, D. Dew-Hughes e D. J. Edwards. "Subharmonically pumped BSSCO microwave mixers operated at Ka band and 77 K". Superconductor Science and Technology 8, n.º 8 (1 de agosto de 1995): 613–16. http://dx.doi.org/10.1088/0953-2048/8/8/003.
Texto completo da fonte
50
Zhi-ming, Zhang, Li Xian-feng e Zhou Shi-kang. "Photon statistics of the micromaser with ultra cold Λ-type three-level atoms". Acta Physica Sinica (Overseas Edition) 8, n.º 8 (agosto de 1999): 571–76. http://dx.doi.org/10.1088/1004-423x/8/8/003.
Texto completo da fonte